BioCanRx was announced as a Network of Centres of Excellence on December 15, 2014, with a total of $60 million in funding and commitments from the NCE Program and more than 25 partners.

Its vision is TO CURE PATIENTS AND ENHANCE THE QUALITY OF LIFE OF THOSE LIVING WITH CANCER and its mission is to ACCELERATE TO THE CLINIC THE MOST PROMISING CANCER BIOTHERAPEUTICS DESIGNED TO SAVE LIVES AND ENABLE A BETTER QUALITY OF LIFE.

Its mandate it to be a global leader in the translation, manufacture and adoption of innovative cancer biotherapeutics for the benefit of all cancer patients by working in partnership with academia, industry, government, patients, charities and NGOs to identify, develop and de-risk promising cancer biotherapies.

BioCanRx is committed to excellent science in a field with great promise. Its focus is on translating this science into what we hope will be significantly better therapies for cancer patients. BioCanRx funds translational projects to accelerate the development of these therapies from the laboratory to the clinic. To that end, it has a goal of advancing four new cancer biotherapies into Canadian-led clinical trials by 2020.